Real-world treatment outcomes in patients with advanced renal cell carcinoma who receive axitinib plus pembrolizumab in the first-line setting in Canadian cancer centers.
Carissa Beaulieu(University of Alberta), Naveen S. Basappa, Simon Tanguay(McGill University Health Centre), Rodney H. Breau(University of Ottawa), Aly‐Khan A. Lalani(Juravinski Cancer Centre), Bimal Bhindi, Georg A. Bjarnason(Sunnybrook Health Science Centre), Denis Soulières(Centre Hospitalier de l’Université de Montréal), Sunita Ghosh(Tata Memorial Hospital), Lori Wood(Dalhousie University), Vincent Castonguay(Centre hospitalier universitaire de Québec), Antonio Finelli(University Health Network), Rahul Bansal(St. Joseph’s Healthcare Hamilton), McKayla Kirkpatrick(University of Alberta), Jeffrey Graham(University of Calgary), Daniel Yick Chin Heng(University of Calgary), Camilla Tajzler
Cited by 1
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I
|The Journal of Urology|2020|268
Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma
|Journal for ImmunoTherapy of Cancer|2018|267
Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).
|Journal of Clinical Oncology|2014|233
Metabolomic adaptations and correlates of survival to immune checkpoint blockade
|Nature Communications|2019|225